Yumanity has found that “strategic alternative” it started searching for early this year as its share price shriveled, forcing deep staff cuts.
The suffering biotech has agreed to sell off most of its pipeline — including a partially-held Phase I Parkinson’s drug and unpartnered discovery-stage neuroscience product candidates — to...
